Alitretinoin

Alitretinoin

SCHEMBL18666

CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

RARARARBRARGRXRARXRBRXRG

The experimentally established mechanism targets of Alitretinoin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA known ✓ P19793 5/20 1.00
RARA known ✓ P10276 4/20 1.00
RARB known ✓ P10826 4/20 1.00
RARG known ✓ P13631 4/20 1.00
RXRB known ✓ P28702 2/20 1.00
RXRG known ✓ P48443 2/20 1.00
ALDH1A1 P00352 12/20 1.00
MAPT P10636 9/20 1.00
CYP3A4 P08684 6/20 1.00
PTGS1 P23219 4/20 1.00
APP P05067 4/20 1.00
SNCA P37840 4/20 1.00
MAPK1 P28482 3/20 1.00
ALOX15 P16050 3/20 1.00
RORC P51449 2/20 1.00
ADORA3 P0DMS8 2/20 1.00
HTR2B P41595 2/20 1.00
BLM P54132 2/20 1.00
HIF1A Q16665 2/20 1.00
DRD3 P35462 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tretinoin SCHEMBL3146 1.00 ALDH1A1 (1.00) ALDH1A1MAPTCYP3A4RXRARARA
Isotretinoin SCHEMBL9123793 1.00 ALDH1A1 (1.00) ALDH1A1MAPTCYP3A4RXRARARA
Tretinoin SCHEMBL8399912 1.00 ALDH1A1 (1.00) ALDH1A1MAPTCYP3A4RXRARARA
Tretinoin SCHEMBL7846921 1.00 ALDH1A1 (1.00) ALDH1A1MAPTCYP3A4RXRARARA
Tretinoin SCHEMBL24982760 1.00 ALDH1A1 (1.00) ALDH1A1MAPTCYP3A4RXRARARA
Isotretinoin SCHEMBL38299 1.00 ALDH1A1 (1.00) ALDH1A1MAPTCYP3A4RXRARARA
Tretinoin SCHEMBL24982761 1.00 ALDH1A1 (1.00) ALDH1A1MAPTCYP3A4RXRARARA
Alitretinoin SCHEMBL5331051 1.00 ALDH1A1 (1.00) ALDH1A1MAPTCYP3A4RXRARARA
Tretinoin SCHEMBL18667 1.00 ALDH1A1 (1.00) ALDH1A1MAPTCYP3A4RXRARARA
Isotretinoin SCHEMBL20603086 1.00 ALDH1A1 (1.00) ALDH1A1MAPTCYP3A4RXRARARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 41772 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122079842-A Method for efficiently preparing hydroxy pinacolone 9-cis retinoic acid ester 2026-05-26 CN claimed
CN-122075739-A CircRNA-LNP delivery system for in-vivo induction generation of iTreg, and preparation method and application thereof 2026-05-26 CN claimed
CN-118873499-B Preparation and application of multifunctional nano preparation for activating tumor in-situ vaccine to generate immune response CHINA PHARMACEUTICAL UNIVERSITY (CN) 2026-05-26 CN claimed
WO-2026104588-A1 UROLITHIN COMBINATION AMAZENTIS SA (CH) 2026-05-21 WO claimed
EP-4743074-A1 METHODS OF TREATING HEMATOLOGIC CANCER Foghorn Therapeutics Inc. (US) 2026-05-20 EP claimed
EP-3841097-B1 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) 2026-05-20 EP claimed
WO-2025251988-A9 REAGENT COMBINATION OR KIT FOR CONSTRUCTING EMBRYOID AND USE THEREOF 广州国家实验室 2026-05-15 WO claimed
US-20260125650-A1 METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES TRAILHEAD BIOSYSTEMS INC (US) 2026-05-07 US claimed
US-20260108619-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2026-04-23 US claimed
US-20260108476-A1 2,4 DNP and Prodrugs Thereof for Treatment of Cancer MITOCHON PHARMACEUTICALS, INC. (US) 2026-04-23 US claimed
US-4857525-A Quaternary ammonium retinoates, their use in cosmetics and in dermopharmacy L'OREAL (FR) 1989-08-15 US claimed
WO-1989006977-A1 FORMULATION AND USE OF RETINOIDS IN TREATMENT OF CANCER AND OTHER DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1989-08-10 WO claimed
EP-0266992-A2 Prevention of glucocorticoid-induced skin atrophy ORTHO PHARMACEUTICAL CORPORATION (US) 1988-05-11 EP claimed
WO-1987007604-A1 DERIVATIVES OF ALL-TRANS- AND 13-CIS RETINOIC ACID AND METHODS FOR PREPARING SAME WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 1987-12-17 WO claimed
US-4713244-A Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent BAUSCH & LOMB INCORPORATED (US) 1987-12-15 US claimed
EP-0212959-A2 Sustained-release formulation containing an amin acid polymer with a lower alkyl (C1-C4) polar solvent BAUSCH & LOMB INCORPORATED (US) 1987-03-04 EP claimed
US-4214000-A Zinc salt of all-trans-retinoic acid for the treatment of acne JOHNSON & JOHNSON (US) 1980-07-22 US claimed
US-4190594-A ABSORBERS OF ULTRAVIOLET RADIATION JOHNSON & JOHNSON (US) 1980-02-26 US claimed
US-4108880-A ULTRAVIOLET ABSORBERS JOHNSON & JOHNSON (US) 1978-08-22 US claimed
US-3984544-A Retinoic acid esters of steroids of the pregnane series, their use in the treatment of acne and pharmaceutical formulations useful therefor SCHERING CORPORATION (US) 1976-10-05 US claimed